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The leading malaria vaccine candidate, RTS,S, based on the Plasmodium falciparum circumsporozoite protein (CSP), will likely
be the first publicly adopted malaria vaccine. However, this and other subunit vaccines, such as virus-vectored thrombospondin-
related adhesive protein (TRAP), provide only intermediate to low levels of protection. In this study, the Plasmodium berghei
homologues of antigens CSP and TRAP are combined. TRAP is delivered using adenovirus- and vaccinia virus-based vectors in a
prime-boost regime. Initially, CSP is also delivered using these viral vectors; however, a reduction of anti-CSP antibodies is seen
when combined with virus-vectored TRAP, and the combination is nomore protective than either subunit vaccine alone. Using
an adenovirus-CSP prime, protein-CSP boost regime, however, increases anti-CSP antibody titers by an order of magnitude,
which is maintained when combined with virus-vectored TRAP. This combination regime using protein CSP provided 100%
protection in C57BL/6 mice compared to no protection using virus-vectored TRAP alone and 40% protection using adenovirus-
CSP prime and protein-CSP boost alone. This suggests that a combination of CSP and TRAP subunit vaccines could enhance
protection against malaria.
There are approximately 3.4 billion people at risk of malariainfection, 207 million cases and 627,000 deaths annually (1).
An effective vaccine could have a greater impact than any other
intervention (2, 3), and yet such a vaccine remains elusive.
Sterile protection against blood-stage malaria infection in both
animal models and humans can be obtained by vaccination with
whole radiation-attenuated sporozoites (spz) (4–6) or genetically
attenuated parasites (7–11) incapable of developing beyond the
liver stage. Difficulties associated with cost, production, and de-
ployment of whole-parasite malaria vaccines to regions where ma-
laria is endemic make it unlikely that such vaccines will play a
central role in the control or eradication of malaria in the near
future.
Subunit vaccines, consisting of single or multiple antigens
from various stages of the malaria parasite, have been a focus of
research development. These include the preerythrocytic-stage
antigens circumsporozoite (CS) protein (12) and thrombos-
pondin-related adhesive protein (TRAP) (13), the blood-stage
antigens MSP-1 (14, 15), AMA-1 (16), and RH-5 (17), and the
Plasmodium vivax antigen Duffy binding protein (18, 19); the
transmission-blocking antigens Pfs25, Pvs25, Pfs230, and
Pfs48/45 have also been investigated as potential subunit vac-
cines (20–23).
The current leading malaria vaccine candidate, RTS,S, is a sub-
unit vaccine undergoing phase III clinical trials in Africa (12). This
vaccine consists of part of the CS protein of Plasmodium falcipa-
rummalaria fused to the hepatitis B virus surface antigen (HBsAg)
and coexpressed in yeast with HBsAg. The vaccine is administered
as a protein-in-adjuvant formulation. The most recent results in-
dicate that administering three doses of RTS,S protects 37% of
infants (24) and 47% of children (12) against severe malaria.
Adenoviral-poxviral prime-boost protocols have been devel-
oped to maximize protective efficacy using viral-vectored vaccines
(25). Viral vectored vaccines using chimpanzee adenoviral vector
(ChAd63) or modified vaccinia strain Ankara (MVA) to deliver
antigens show great promise, stimulating high T-cell responses
(26–28). Multi-epitope TRAP (ME.TRAP) antigen delivered us-
ing virus-vectored vaccines produces very high levels of sterile
protection in rodents (29), and in a recent phase IIa clinical trial
(27) it was determined that this vaccine in a ChAd63-MVA prime-
boost regime induced sterile protection in 21% of human volun-
teers.
With less than half of human volunteers seeing protective ef-
fects in recent trials, there is clearly a requirement for an im-
proved, potent malaria vaccine. One potential improvement
could be in combining two subunit vaccines to achieve enhanced
protection. This is the approach explored here, using two of the
leading malaria vaccine candidates, CSP and TRAP, and a com-
monly used murine model of malaria using Plasmodium berghei
(30); murine models represent an inexpensive and useful way to
examine vaccines in a preclinical setting before progression to
human trials. CSP is involved in parasite motility and attachment
and invasion of the liver of the vertebrate host (31). The first
demonstration of anti-CSP antibody (Ab)-mediated protection
was inP. berghei (32), and CD8T cells also play a role (33). TRAP
also facilitates invasion of the liver (34, 35) and is involved in
parasite motility (35, 36); P. berghei TRAP-specific CD8 T cells
have been shown to inhibit the liver stage (37).
Either CSP or TRAP used individually in a vaccine provides
suboptimal levels of protection. In this study, their combination
was tested and optimized.
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MATERIALS AND METHODS
Protein expression and purification. The mammalian codon optimized
P. berghei CSP and TRAP genes were cloned into the pHLsec plasmid with
the His tag at the 3= end under the control of CMV enhancer and chick
beta-actin promoter (38). DNA constructs were produced in Escherichia
coli DH5 (Life Technologies) cells and purified using an endotoxin-free
Plasmid Mega Kit (Qiagen). HEK-293T cells were transiently transfected
using a DNA-polyethylenimine mix. This resulted in secreted proteins
with N-terminal ETG and C-terminal GTK(His6) tags. The conditioned
media with secreted proteins were dialyzed against phosphate-buffered
saline (PBS), and proteins were purified by immobilized Co2-affinity
chromatography, followed by size exclusion chromatography in 20 mM
Tris-HCl (pH 8.0)–300 mM NaCl. Protein size was verified by Western
blotting with the PentaHis monoclonal primary antibody (1:1,000 dilu-
tion; Qiagen) and goat anti-mouse IgG peroxidase-conjugated secondary
antibody (1:2,000; Sigma).
Animals. The age-matched, 6-week-old female inbred C57BL/6 (H-
2b) and outbred CD1 (ICR) strains of mice used in this study were pur-
chased from Harlan (USA). All animals and procedures were used in
accordance with the terms of the UK Home Office Animals Act Project
License. Procedures were approved by the University of Oxford Animal
Care and Ethical Review Committee.
Viral vector vaccines. The PbCSP insert in viral vectored and
protein vaccines was full length without modification (GenBank ac-
cession no. P23093.1). The PbTRAP insert (GenBank accession no.
AAB63302.1) in viral vectors was modified by removal of the transmem-
brane domain, and a tPA (human plasminogen activator; GenBank acces-
sion no. K03021) leader sequence was inserted in the upstream region of
the gene, replacing the native endogenous leader sequence, since it has
been suggested that this adjustment facilitates antigen expression within
the host cells (39). In addition, the transmembrane (TM) domain or gly-
cosylphosphatidylinositol anchor was removed from PbTRAP by intro-
ducing two stop codons in order to maximize protein secretion from any
virus-transduced cell (40).
Prior to immunization animals were anesthetized using an inhalation
chamber containing a mixture of gases, isoflurane (23.5%) and oxygen
(12 L/min). Mice were primed with simian adenoviral vector 63
(ChAd63) encoding different transgenes at a dose of 108 infectious units
(IU) and 8 weeks later boosted with vaccinia virus-modified virus strain
Ankara (MVA) encoding the relevant transgene at a concentration of 107
PFU/ml, unless stated otherwise. All viral vector vaccines were adminis-
tered intramuscularly in endotoxin-free PBS. Vaccinations with two dif-
ferent transgenes in coadministration groups were carried out either with
each vaccine injected into the left or right thigh muscle separately or with
the mixture of both vaccines administered in a single thigh muscle, as
indicated in Results. All recombinant ChAd63 and MVA viral vectors
used throughout this study were generated at the Jenner Institute’s vector
core facility.
Protein vaccines. All recombinant protein vaccinations were admin-
istered intramuscularly as a 50-l dose containing sterile PBS and 15g of
protein formulated with 5 l of Abisco 100 adjuvant (provided by the
Jenner Institute adjuvant bank). For the viral vector and protein mixture
group, a 50-l vaccine dose comprised PBS, MVA expressing the relevant
transgene, and 15 g of the recombinant protein formulated with 5 l of
Abisco 100 adjuvant.
Whole IgG ELISA. Enzyme-linked immunosorbent assays (ELISAs)
measuring total IgG were carried out as described previously (41). In brief,
blood was collected from mice using tail vein bleeds and stored overnight
at 4°C. On the following day, the tubes were spun at 13,000 rpm for 4 min,
and the serum was collected and stored at 4°C until the assay. Nunc Im-
muno Maxisorp Plates were coated with protein diluted in PBS to a con-
centration of 1g/ml, followed by incubation overnight at room temper-
ature. Plates were washed with PBS– 0.05% Tween 20 (PBS/T) and
blocked with 10% skimmed milk powder in PBS/T. Sera were diluted,
typically at a starting concentration of 1:100, added into duplicate wells,
and serially diluted 3-fold down the plate. Plates were incubated for 2 h at
room temperature and then washed as described before. Goat anti-mouse
whole IgG conjugated to alkaline phosphatase was added for 1 h at room
temperature. After a final wash, p-nitrophenylphosphate at 1 mg/ml in
diethanolamine buffer was used as a developing substrate. The optical
density at 405 nm (OD405) was read using a model 550 microplate reader.
Serum antibody endpoint titers were taken as the x axis intercept of the
dilution curve at an absorbance value three standard deviations greater
than the OD405 for serum from a naive mouse. A standard positive serum
sample and naive serum sample were added as controls for each assay.
Naive mouse serum was negative for antigen-specific responses against all
of the recombinant proteins used.
Peptides. Crude 20-mer peptides overlapping by 10 amino acids and
representing full-length P. berghei CSP and TRAP were synthesized by
Mimotopes. Peptides were reconstituted in dimethyl sulfoxide at a con-
centration of 50 mg/ml. The peptides were combined into a single pool or
three different subpools for their use in intracellular cytokine staining
(ICS) and ex vivo gamma interferon (IFN-) enzyme-linked immunospot
(ELISPOT) assays, respectively, at a final individual peptide concentration
of 5 g/ml.
Splenocyte preparation. Naive mice were sacrificed by cervical dislo-
cation, and their spleens were removed. The spleens were homogenized in
PBS and passed through a 70-m-pore-size cell strainer, and cells were
pelleted by centrifugation at 500  g for 5 min. The cell pellet was then
treated with ammonium chloride-potassium (ACK) lysis buffer for 5 min
before being washed with 25 ml of PBS. Splenocytes were then immedi-
ately centrifuged at 500 g for 5 min, and the resulting pellet was resus-
pended in 10 ml of complete medium (D10) per spleen. Total number of
splenocytes was determined by CASY counter and adjusted to 107 cells per
ml of complete medium for use in ex vivo IFN- ELISPOT assays.
Ex vivo IFN- ELISPOT assay. Ex vivo IFN- ELISPOT assays were
carried out using peripheral blood mononuclear cells (PBMCs) isolated
from blood as previously described (42). In brief, nitrocellulose-bot-
tomed 96-well Multiscreen HA filtration plates were coated with anti-
mouse IFN- monoclonal antibody (MAb) overnight at 4°C. PBMCs
were isolated from peripheral blood collected from tail vein bleeds into
200 l of 10 mM EDTA/PBS. Erythrocytes were lysed using ACK lysis
buffer, and PBMCs were harvested using centrifugation. The cells were
washed, resuspended in complete medium, and counted using a CASY
counter, and 50 l of culture was plated into duplicate wells. A 50-l
portion of each of the peptide subpools diluted in medium plus 250,000
naive splenocytes was added to test wells as a source of antigen-presenting
cells. Medium and naive splenocytes were also plated onto the negative-
control wells. Plates were incubated at 37°C in 5% CO2 for approximately
18 h. The plates were then washed and incubated with biotinylated anti-
mouse-IFN- MAb (Mabtech), followed by incubation with a streptavi-
din alkaline phosphatase polymer. Spots were developed by addition of
color development buffer and counted using an ELISPOT reader and
accompanying software. Results are expressed as spot-forming units
(SFU) per million PBMC. Background responses in medium-only wells
were subtracted from those measured in wells stimulated by one of three
peptide subpools.
Isolation of liver-resident lymphocytes. Livers from mice were per-
fused with PBS and dissected, mashed, and passed through a 100-m-
pore size filter. The liver cells were centrifuged at 1,350 rpm for 7 min, and
the pellet was resuspended in 15 ml of 33% isotonic Percoll and then
centrifuged at 693  g for 12 min without brake. Cell debris and the
supernatant were removed. The pellet was resuspended in 2 ml of ACK,
and the erythrocytes were lysed for 5 min. Then, 25 ml of PBS was added,
followed by centrifugation at 1,500 rpm for 5 min. The lymphocytes were
washed with complete minimal essential medium (MEM) and resus-
pended in 500 l of complete MEM.
ICS. For intracellular cytokine staining (ICS), ACK lysis buffer-treated
whole-blood PBMCs were incubated for 5.5 to 6 h in the presence of a
peptide pool representing the antigen of interest at individual peptide
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concentrations of 5 g/ml. Golgi-Plug (BD Biosciences) (1 l/ml) and
anti-CD107a PE (clone eBio/D4B) at a final dilution of 1:200 were also
included. Phenotypic analysis of CD8 and CD4 T cells was performed
by staining PBMCs using the following antibody clones: anti-CD8 PerCP-
Cy5.5 (clone 53-6.7) and eFluor 650-coupled anti-CD4 (GK1.5) and anti-
IFN- APC (XMG1.2) (BD Biosciences). Also, the surface staining of
liver-resident lymphocytes was performed using the following antibodies:
anti-NK1.1 FITC, anti-CD3 Alexa Fluor 700, anti-CD69 PE-Cy 7, anti-
CD8 eFluor 450 (BD Biosciences). The liver-resident invariant natural
killer T cells (iNKT cells) were stained with CD1d tetramer conjugated to
PE. Nonspecific binding of antibodies was prevented by incubating with
anti-CD16/CD32 Fc III/II receptor prior to staining. Flow cytometric
analyses were performed using an LSRII instrument. Data were analyzed
using either FACSDiva or FlowJo software. Analysis of multifunctional
CD8 T-cell responses was performed using Boolean analysis in FlowJo
software, Pestle, and SPICE 4.0 kindly provided by M. Roederer (National
Institutes of Health, Bethesda, MD).
In vivo CD8 and CD4 T-cell depletions. The T-cell depletions
were performed as described previously (43). Briefly, in vivo-depleting
MAbs were purified by protein G affinity chromatography columns from
hybridoma culture supernatants. Anti-CD4 GK1.5 (rat IgG2a) and anti-
CD8 2.43 (rat IgG2a) were sterile filtered and diluted in sterile PBS. Nor-
mal rat IgG (nRatIgG) was purchased from Sigma and purified by the
same method. For depletion of CD4 or CD8T cells, mice were injected
intraperitoneally with 200 g of the relevant MAb on days 2 and 1
before and on the day of challenge. Depletion of CD4 and CD8 T cells
was confirmed by flow cytometry of surface-stained PBMCs from de-
pleted and control mice a day after the challenge.
In vivo Kupffer and NK cell depletions. The in vivo depletion of
liver-resident Kupffer cells was accomplished by intravenous administra-
tion of liposome formulated clodronate 48 h prior to challenge at a con-
centration of 10l of suspension per 1 g of mouse (44). Control liposomes
containing PBS were also included. To deplete natural killer (NK) cells,
mice received a single dose of 200l of anti-asialo GM1 antiserum diluted
1:8 in 0.5 PBS on days2, 0, and2 relative to challenge, as described
previously (45). Naive rabbit serum was also used as a control (kindly
provided by A. Douglas). NK cell depletion was confirmed by flow cytom-
etry of surface-stained PBMCs from depleted and control mice 3 days
after the challenge.
Sporozoite neutralization assay. Sporozoite neutralization assay was
performed as described previously (32). At room temperature 50,000 sal-
ivary gland wild-type P. berghei sporozoites were incubated with either
undigested 3D11 or 3D11 Fab in total of 0.5 ml of RPMI 1640. After a
30-min incubation, 500 l of ice-cold RPMI 1640 was added, and all
sample tubes were placed on ice. Immediately thereafter, 100l of culture
containing 5,000 sporozoites was injected intravenously (i.v.) into each
animal.
Fragmentation of 3D11. Fab fragments of 3D11 MAb were generated
by incubation with immobilized Ficin in the presence of 25 mM cysteine
according to the manufacturer’s instructions (Thermo Scientific Pierce).
Fab fragments were purified by passing twice over a protein A column.
The purity of Fab fragments was verified by nonreducing SDS-PAGE.
Transgenic (tg) P. berghei expressing firefly luciferase. The tg P.
berghei parasites (PbGFP-Luccon) used in these studies expressed fusion
GFP (mutant 3) and firefly luciferase (LucIAV) gene under the control of
constitutive EF1a promoter (46). The parasites were generated by a stable
double-crossover homologous integration of the transgene into the P230p
locus of the P. berghei reference line ANKA clone cl15cy1. The tg parasite
was kindly provided by Oliver Billker from Wellcome Trust Sanger Insti-
tute, Hinxton, United Kingdom.
Parasite preparation. Female A. stephensi mosquitoes were fed on
phenylhydrazine (PHZ)-treated female TO mice infected with P. berghei
parasites. At 21 days after the feed, the mosquitoes were dissected, the
salivary glands were isolated, and the salivary gland sporozoites were ex-
tracted and diluted in RPMI 1640. The total number of sporozoites was
determined using a hemocytometer, and specified quantities were in-
jected i.v. into mice.
Thin-blood smears to assess parasitemia. Thin-blood smears were
prepared on glass slides from a drop of blood obtained from a tail clip. The
blood smear was allowed to air dry before fixation with methanol and
stained for at least 1 h using 5% Giemsa diluted in distilled H2O. The slides
were then removed and allowed to air dry at room temperature.
Statisticalmodeling to predict parasitemia.To obtain the time taken
to reach 1% blood-stage parasitemia, a linear regression model was used,
as described previously (29). Briefly, blood parasite counts were obtained
for 3 to 5 consecutive days, twice a day, starting on day 4 after challenge.
The logarithm to base 10 of the calculated percentage of parasitemia was
plotted against time after challenge. The Prism 5 (GraphPad) statistical
analysis package was used to generate a linear regression model using the
linear part of the blood-stage growth curve. From this, the time taken to
reach 1% parasitemia was obtained, expressed in days postchallenge. As
expected for vaccines containing only preerythrocytic-stage antigens, all
infected mice exhibited similar exponential blood stage growth regardless
of treatment group. The time to reach 1% parasitemia was used in survival
analyses to assess vaccine efficacy; mice without detectable parasitemia
after 15 days were considered to have complete sterile protection. This
approach has been used previously; the time to blood-stage parasitemia
reflects the number of parasites erupting from the liver, provided there is
no blood-stage immunity (47).
In vivo imaging system (IVIS). The bioluminescent luciferase signal
(BLS) was detected by imaging whole animals using the in vivo IVIS 200
imaging system, as described previously (48). Briefly, after intravenous
injection of tg P. berghei sporozoites, the animals were anesthetized using
an isoflurane chamber at a different time points depending on the exper-
iment. Prior to imaging, 100l of D-luciferin substrate dissolved in sterile
PBS to a concentration of 50 mg/kg was subcutaneously injected into the
neck region of mice. Animals were imaged for 60 to 180 s at a binning
value of 8 and field of view (FOV) of 12.8 cm, 8 min after the injection of
the substrate. Mice remained anesthetized throughout the procedure.
Quantification of BLS was performed using Living Image 4.2 image anal-
ysis software. Regions of interest were created around the liver area of the
mouse body and kept constant for all animals. The measurements were
expressed on a log scale as total flux of photons emitted from animals
adjusted per second of exposure time.
Statistics. GraphPad Prism 5.0 for Mac OS was used for all statistical
analysis unless indicated otherwise. The Kolmogorov-Smirnov test for
normality was used to determine whether the values followed a Gaussian
distribution prior to statistical analysis when comparing two or more
populations. An unpaired t test was used to compare two normally dis-
tributed groups, whereas the Mann-Whitney rank test was used to com-
pare two nonparametric groups. If more than two groups were present,
the nonparametric data were compared using the Kruskal-Wallis test with
Dunn’s multiple-comparison posttest, whereas normally distributed data
were analyzed by one-way analysis of variance (ANOVA) with Bonferro-
ni’s multiple-comparison posttest. The effect of two variables was ex-
plored using two-way ANOVA with Bonferroni’s multiple-comparison
posttest. Correlation strength was tested using either Pearson’s or Spear-
man’s tests as indicated in the results section. Kaplan-Meier survival
curves were used to represent protective efficacy to challenge with P. ber-
ghei. When required, protection was also assessed using IVIS in vivo im-
aging and data log10 transformed prior to analysis. All ELISA titers were
also log10 transformed before analysis. A P value of0.05 was considered
statistically significant (*, P 0.05; **, P 0.01; ***, P 0.001; ****, P
0.0001).
RESULTS
Combining virus-vectored CSP and TRAP vaccines fails to im-
prove protective efficacy.CSP and TRAP vaccines, by themselves,
elicit immune responses and some degree of protection (12, 24,
26, 27). In the present study, these vaccines were combined with
Bauza et al.
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the aim of providing enhanced immunity in mice to rodent ma-
laria Plasmodium berghei. Virus-vectored vaccines, adenovirus
prime and MVA boost (Ad-M) PbCS and Ad-M PbTR, were tri-
aled both separately and together as a combination vaccine on
inbred C57BL/6 and outbred CD1 mice. A heterologous prime-
boost regimen using replication-deficient ChAd63 (Ad) and mod-
ified vaccinia virus strain Ankara (M) with an 8-week interval was
used to deliver the antigens. This regime was previously found to
optimize immune responses (27, 41).
The combination vaccine (Ad-M CS  Ad-M TR [Ad-M
CSTR]) produced better protection against sporozoite chal-
lenge than either component trialed alone, but this improvement
was not significantly better than the protection achieved by Ad-M
TR, according to a prediction of time taken to reach 1% blood-
stage parasitemia in C57BL/6 after challenge with 2,000 sporozo-
ites (spz) per mouse (Fig. 1A). The Ad-M CSTR achieved a delay
to 1% parasitemia of 6.7 days, while the Ad-M CS and Ad-M TR
vaccines yielded delays of 5.6 and 6.4 days, respectively; all three
vaccination groups took significantly longer to reach 1% para-
sitemia than the 4.7 days taken in mice vaccinated with an Ad-M
vehicle control (P 0.0001) (Fig. 1A). The levels of sterile protec-
tion achieved in CD1 mice showed a similar effect, with 50% of
animals vaccinated with Ad-M CS, Ad-M TR, and Ad-M CSTR
vaccines exhibiting sterile protection compared to no sterile pro-
tection seen with animals injected with Ad-M vehicle control (Fig.
1B). Since all C57BL/6 showed blood-stage parasitemia, a bar
graph was judged the clearest way to present these results, whereas
for mixed outcome with CD1, a Kaplan-Meier curve was the most
clear.
Humoral and cellular immune responses to the combination
vaccine were compared to those of mice vaccinated with the Ad-M
CS and Ad-M TR components. Figure 2Ai shows that the combi-
nation vaccine elicits significantly lower antibody titers against the
CS protein than does the Ad-M CS vaccine used alone; the same is
true of anti-TRAP antibody titers when the combination is com-
pared to Ad-M TRAP (Fig. 2Aii). This evidence of antigenic inter-
ference could explain why the combination vaccine did not work
significantly better than the Ad-M TR vaccine.
Taken together these data suggested that the combination vac-
cine had some potential but required further optimization. To this
end, experiments were performed to elucidate the mechanism of
protection of the combination vaccine, as detailed below.
In the Ad-MCSTR combination vaccine, protection isme-
diated by antibodies against PbCS and aCD8 response against
PbTRAP. ICS showed that high CD8 IFN- T-cell responses
were seen only in response to PbTRAP, whereas no significant
CD4 responses were seen except for a small but detectable re-
sponse with PbTRAP using the Ad-M CSTR regime (Fig. 2Bi
and Bii). In an experiment examining the mechanisms of protec-
tion of the Ad-M CS, Ad-M TR, and Ad-M CSTR vaccines,
either CD8 or CD4 T cells were depleted in vaccinated and
control C57BL/6 mice. Neither CD8 nor CD4 T-cell depletion
affected liver-stage burden in Ad-M CS-vaccinated mice com-
pared to the control (Fig. 3Ai), and there was a strong correlation
between the endpoint CSP Ab titer and the time to 1% blood-stage
infection (Fig. 3Bi), suggesting that antibodies help mediate pro-
tection in this Ad-M CS regimen. A correlation was not seen be-
tween CSP T-cell SFU and time to 1% blood-stage infection (Fig.
3Bii). CD8 but not CD4 T-cell depletion abrogated the protec-
tive effect of Ad-M TR (Fig. 3Aii) and Ad-M CSTR (Fig. 3Aiii)
vaccinations, suggesting that CD8 T cells contribute to protec-
tion in these regimes; flow cytometry confirmed successful deple-
tion of CD4 and CD8 T cells (Fig. 3C).
High levels of anti-PbCS Ab are required for protection
against P. berghei challenge in C57BL/6 mice. 3D11 is an MAb
against the repeat region of PbCS (32). It was used to determine
the antibody titers required to achieve sterile protection against P.
berghei challenge. Administration of 3D11 in three intravenous
injections of 300 g each, producing antibody levels of	5 ELISA
units, was sufficient to produce sterile protection against 2,000
sporozoites in all challenged animals (Fig. 4A and B). This dem-
onstrated that high levels of antibody production by a PbCS vac-
cine would be required to achieve sterile protection of vaccinated
mice.
Trialed with Ad-M TR in a combination regime, sterile protec-
tion was achieved with much lower dosages of 3D11 than required
with 3D11 alone (Fig. 4C). Sterile protection of all mice using the
3D11-TR combination vaccine was achieved with three injections
of 150g of 3D11 MAb each. This experiment demonstrated that
an Ad-M CSTR vaccine is able to achieve better protection
FIG 1 C57BL/6 mice and CD1 outbred mice were vaccinated using a prime-
boost strategy. Viral vectors containing either PbTRAP or PbCSP were intra-
muscularly injected into the thigh muscles of the mice, with 108 IU of ChAd63,
followed by MVA at 107 PFU/ml 8 weeks later. Mice vaccinated using the
combination vaccine were injected with Ad-M TR in one thigh and Ad-M CSP
in the other. The vehicle control used empty ChAd63 and MVA-GFP-OVA.
Two weeks after boost vaccination mice were challenged by i.v. injection of
2,000 P. berghei sporozoites. The protective efficacy is here presented as time
predicted to reach 1% blood-stage parasitemia using a linear regression model.
Blood-stage parasitemia was monitored from day 4 postchallenge. (A) Time to
1% blood-stage parasitemia in C57BL/6 mice (n
 6 per group). (B) Time to
1% blood-stage parasitemia in outbred CD1 mice. *, P  0.05; **, P  0.01;
***, P 0.001; ****, P 0.0001 (determined by one-way ANOVA with Bon-
ferroni’s multiple-comparison posttest).
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against malaria than the components alone, and thus provided
proof of concept for a combination vaccine.
An Ad-P CS/Ad-M TR combination vaccine confers sterile
protection to C57BL/6 mice. Using an Ad-P CS vaccine with 15
g of recombinant PbCS in Abisco 100 as a boost produced al-
most 10-fold-higher titers of anti-PbCS antibody than did the
Ad-M CS vaccine (Fig. 5A). This order-of-magnitude increase was
maintained when the Ad-P CSP vaccine was combined with the
Ad-M TR vaccine. Unlike with the Ad-M CSPTR combination
vaccine, no antigenic interference was seen when Ad-P CSP and
Ad-M TR were injected into separate sites. A slight but statistically
significant decrease in antibody titers was seen when Ad-P CS and
Ad-M TR were mixed and injected into the same site (Fig. 5A).
The Ad-P CS vaccine, despite achieving anti-PbCS Ab titers as
high as conferred sterile protection using 3D11 MAb, conferred
sterile protection on a nonsignificant number of mice in one ex-
periment (Fig. 5B) and on no mice in another (Fig. 5C) after
challenge with 2,000 P. berghei spz.
The combination regimen, whether CSP and TRAP vaccines
were injected into separate legs (Fig. 5B) or mixed and coinjected
(Fig. 5C), consistently conferred superior levels of sterile protec-
tion compared to the Ad-P CSP or Ad-M TR vaccines alone. Ad-P
CS and Ad-M TR administered as a combination vaccine into
separate sites produced sterile protection in 100% of mice, sug-
gesting that the increase in antibody titers caused by Ad-P CS
compared to Ad-M CS was sufficient to improve the combination
CS-TR vaccine to the desired level of efficacy, as suggested by the
results given above (Fig. 4C). Thus, the CSTR vaccine was suc-
cessfully tailored to achieve the desired results.
In the 3D11Ad-M TR combination vaccine, protection is
mediated by antibodies in an Fc-independent fashion. NK cells
and CD8 T cells are important mediators of protection. The
mechanisms responsible for the effectiveness of the Ad-P
CSAd-M TR combination vaccine were examined. These mech-
anisms were investigated using 3D11 MAb instead of Ad-P CS
since it was not practical to optimize the Ad-P CS dosage to a level
required to maximize sensitivity in these experiments.
Removal of the Fc portion of the 3D11 MAb had no effect on
levels of sterile protection compared to intact 3D11 in a sporozoite
neutralization assay (Fig. 6A). This suggests that the mechanism
of protection of 3D11 in this combination vaccine is not via
Fc-dependent phagocytosis by Kupffer cells or other macro-
phages. It could, however, still be mediated by Fc-independent
phagocytosis.
Depleting Kupffer cells had no significant effect on the protec-
tion conferred by the Ad-M TR3D11 vaccine (Fig. 6B). Deplet-
ing NK cells, on the other hand, did decrease the protection asso-
ciated with this vaccine (Fig. 6B), suggesting that NK cells may
play an important role in the mechanism of protection.
ICS analysis of three cell types from the livers of vaccinated and
unvaccinated and then challenged and unchallenged mice pro-
vided further data on the mechanisms of protection. Vaccinated
mice were found to have more CD8 CD3 T cells than naive
mice and that, of these vaccinated mice, challenged mice have a
higher proportion and higher absolute numbers of CD8 IFN-
cells (Fig. 7A). No significant difference in the numbers or pro-
portions of CD1d CD3 iNKT cells were found between vacci-
nated or challenged mice (Fig. 7B). However, NK cells which are
IFN- were found to be present in higher numbers and in a
higher proportion in vaccinated and challenged mice than in vac-
cinated and unchallenged mice (Fig. 7C). There was found to be a
correlation between NK IFN- cell percentage and CD8
IFN- cells in vaccinated and challenged mice only and not in
other groups (Fig. 7D). From this and the fact that there was found
to be a higher proportion and higher absolute numbers of CD69
NK cells in vaccinated compared to nonvaccinated mice (Fig. 7E),
FIG 2 Humoral and cellular responses following Ad-M vaccinations using
PbCSP and PbTRAP alone and in combination. C57BL/6 mice were vacci-
nated as described in Fig. 1. Two weeks after boost administration and 1 day
before challenge, the humoral and cellular responses to vaccination were as-
sessed using endpoint ELISA and ICS respectively. (A) Whole IgG Ab titers
were measured against PbCSP (i) and PbTRAP (ii) recombinant proteins. No
response was seen in this or subsequent ELISAs to serum from vehicle control
groups. (B) Whole-blood PBMCs were restimulated with single peptide pools
representing the full length of PbTRAP (i) and PbCSP (ii) antigens. The fre-
quencies of CD8 IFN- (left y axis) or CD4 IFN- (right y axis) T-cell
subsets were quantified. *, P 0.05; **, P 0.01; ****, P 0.0001 (as deter-
mined by one-way ANOVA with Bonferroni’s multiple-comparison posttest).
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it appeared that NK cells could be important in the mechanism of
protection conferred by Ad-M TR.
These data, together with other data presented above (Fig.
3), suggest a model for the mechanism of protection of this
combination vaccine whereby 3D11Ad-M TR confers sterile
protection by PbCSP-specific antibodies reducing the number
of sporozoites reaching the liver and CD8 T cells destroying
any hepatocytes infected by the few remaining sporozoites.
With the Ad-P CSPAd-M TR regime, protection may also be
mediated by CSP-specific CD8 T cells and IFN-, as found in
other studies (33, 49–51); however, this was not examined here.
A prediction of this model is that Ad-M TR alone should confer
sterile protection when fewer sporozoites are used in a chal-
lenge. This was found to be the case: in a challenge with 200
sporozoites, Ad-M TR was able to confer sterile protection to
38% of challenged mice (Fig. 6C).
DISCUSSION
Currently, the most protective preerythrocytic-stage malaria
vaccine candidates in human clinical trials—RTS,S and Ad-M
ME.TRAP—rely on the induction of high Ab titers and power-
ful T-cell responses, against CS and TRAP proteins, respec-
tively. However, individually both vaccines elicit only subopti-
mal protection against experimental malaria sporozoite challenge.
Here, a P. berghei mouse malaria model was used to assess the
efficacy of a vaccine combining both antigens.
FIG 3 Depletion of CD4 or CD8T cells in mice vaccinated with Ad-M PbCSP or Ad-M PbTR vaccines. (A) C57BL/6 mice (n
 20 per group) were vaccinated
with Ad-M CSP (i), Ad-M TR (ii), or a combination of both (iii). A vector control group (Ad-M VC) (n
 10) was included. Two weeks after the boost, a selection
of animals from each group (n
 6 per group) were depleted of CD4 or CD8 T cells, using three 200-g intraperitoneal injections of rat GK1.5 or 2.43 MAb,
respectively, on days2,1, and 0 relative to challenge with 5,000P. bergheiGFP/Luc spz. Control rat IgG1 (RIgG) antibodies were used as an injection control
(n
 8 per group). At 44 h after challenge, the BLS emitted from infected animals was quantified. Means with the standard errors of the mean (SEM) are shown.
*, P  0.05; ***, P  0.001; ****, P  0.0001 (as determined by one-way ANOVA with Bonferroni’s multiple-comparison posttest). (B) A strong correlation
between time to reach 1% parasitemia (Tto1) and anti-PbCSP Ab titers (i), but not ex vivo IFN- ELISPOT responses (ii), suggests that protection is mainly
mediated by Abs in Ad-M CSP vaccination. (C) Representative FlowJo plots demonstrate the depletion of CD4 or CD8T cells compared to vaccinated animals
that received control rat IgG1.
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Initially a heterologous chimpanzee adenovirus 63 (Ad) and
modified vaccinia virus strain Ankara (MVA) prime-boost strat-
egy (Ad-M) was used with both PbCS and PbTR antigens. The
Ad-M regimen has been demonstrated to induce strong humoral
and cellular immune responses in mice (29, 43), rabbits (40), rhe-
sus macaques (52), and humans, showing an excellent safety pro-
file in the latter (53, 54) using different malarial antigens. The
combination of these antigens failed to induce significantly supe-
rior protection compared to the most protective single antigen
immunization, however.
The degree of protection observed with Ad-M CSTR combi-
nation vaccine in C57BL/6 mice was substantially lower than that
seen in a study by Schneider et al. (55), where DNA/MVA prime-
boost vaccination employing the combination of the same PbCS
and PbTRAP antigens elicited 60 and 100% sterile protection
against 1,000 and 200 P. berghei sporozoite challenges, respec-
tively. However, in the latter case at the time of boosting MVA was
administered intravenously, which is a more protective mode of
vaccination. Since the intravenous injection of MVA viral vectors
is not permitted in the clinical setting, the intramuscular route of
administration was chosen.
A previous study using human adenovirus serotype 5 com-
bined with WR vaccinia virus encoding P. yoelii CSP (25) detected
higher levels of protection than found here using an Ad-M CSP
regime with P. berghei, probably because of the greater immuno-
genicity of WR vaccinia virus. In a direct comparison, chimpanzee
adenoviruses have been shown to be as immunogenic or more
immunogenic than human adenovirus vaccine vectors (56, 57).
Since a trend toward increased immunity was observed when
PbTRAP and PbCS antigens were coadministered into separate
sites, it seemed likely that this particular combination could offer
a high degree of protective efficacy if it was carefully tailored for
the concurrent induction of higher Ab and T-cell responses. The
MAb 3D11 specific against the central repeat region of PbCS an-
tigen was used to determine anti-PbCS Ab requirements necessary
for sterile protection in a C57BL/6 animal model. As expected, a
clear dose-dependent effect was observed, and an extremely high
concentration of anti-CS 3D11 was required for complete sterile
protection. Substantially smaller amounts of 3D11 were sufficient
for sterile protection if the MAb vaccinations were performed on
previously Ad-M PbTRAP-immunized animals.
Thus, the heterologous Ad prime/protein-in-adjuvant boost
(Ad-P) regimen for the administration of PbCS antigen was ex-
plored, since reports have previously suggested that Ad-P regimen
induces significantly higher Ab responses compared to these reg-
imens administered individually (52, 58, 59). Immunization of
C57BL/6 mice using the Ad-P PbCSP and Ad-M PbTRAP combi-
nation vaccine conferred an exceptionally high level of sterile pro-
tection when each antigen was administered into separate sites.
Interestingly, an Ad-P PbCSP and Ad-M PbTRAP combina-
tion vaccine administered as a mixture into a single site at the time
of prime and boost was less protective than a separate-site vacci-
nation strategy. The mixing of vaccines prior to single-site admin-
istration seemed to increase antigenic interference between
PbTRAP and PbCSP immunogens, resulting in diminished im-
mune responses against individual antigens, which, in part, could
explain the lower level of protective efficacy (60). However, the
challenge against the mixed and coinjected vaccination regime
was more rigorous, as evident from the lower time taken to reach
1% blood-stage parasitemia in naive mice; this, too, could explain
the lower level of protective efficacy. In either case, the combina-
tion of CSP and TRAP vaccines substantially enhanced protection
compared to individual immunizations. Trials combining P. fal-
ciparum CSP and TRAP with other antigens (61, 62) have shown
FIG 4 Enhanced protective effect of 3D11 MAb with the Ad-M PbTR vaccine.
Naive C57BL/6 mice (n
 5 to 6 per group) were injected i.v. with three doses of
anti-PbCSP mouse MAb 3D11 on days3,2, and1 relative to the challenge.
The mice were then challenged with 2,000 P. berghei spz each. A variety of 3D11
dosage sizes were used; these are labeled on each graph. (A) Linear regression
modeling was used to predict Tto1 for parasitized mice. The Tto1 values were
used for Kaplan-Meier analysis. Mice that didn’t develop blood-stage infection
by day 9 still demonstrated sterile protection by day 15 postchallenge. Blood-
stage parasitemia was monitored using Giemsa-stained blood films. (B) 3D11
MAb titers from the serum of treated mice were measured by endpoint ELISA,
immediately before challenge. (C) C57BL/6 mice (n
 5 to 6 per group) were
vaccinated using a heterologous prime-boost regime using ChAd63 and MVA
viral vectors expressing PbTR. The dosage of 3D11 was varied, in combination
with either Ad-M TR or Ad-M VC, and challenged as above. ****, P 0.0001
(as determined by one-way ANOVA with Bonferroni’s multiple-comparison
posttest). Means with the SEM are shown.
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limited protection to date, though these trials did not use the most
protective Ad-M or Ad-P regimes.
The cell depletion experiments performed on Ad-M PbTRAP-
and 3D11 MAb-immunized mice demonstrated that the protec-
tion provided by this combination vaccine was mediated by anti-
PbCS Abs capable of neutralizing a large proportion of spz, with
PbTRAP-specific CD8 T cells and NK cells providing an impor-
tant second line of defense against parasites that manage to estab-
lish intrahepatic infection. The protection provided by highly pro-
tective irradiated spz vaccination has also been shown to be
dependent on cellular and humoral immune responses against
various spz-stage antigens (63). However, the results obtained us-
ing anti-asialo GM1 depleting polyclonal Abs should be inter-
preted cautiously, since the specificity of these Abs has been ques-
tioned (64, 65), and these antibodies may also reduce CD8T-cell
numbers, leading to diminished efficacy.
Anti-CSP Ab-mediated sporozoite neutralization could be ac-
complished by various mechanisms: complement-dependent ly-
FIG 5 A particulate PbCSP vaccine improves antibody responses and response to challenge in a combination vaccine. C57BL/6 mice (n
 6 to 14 per group) were
vaccinated with different regimens according to group as follows: naive control group, GFP antigen using ChAd63 prime and MVA boost; Ad-M TR, PbTRAP
antigen using ChAd63 prime and MVA boost; Ad-M TR (Ab100), PbTRAP antigen using ChAd63 prime and MVA with Abisco 100 boost; Ad-P CSP, PbCSP
antigen using ChAd63 prime and 15 g PbCSP in Abisco 100 boost; and Ad-M PbCSP, PbCSP antigen using ChAd63 prime and MVA boost. In the “Ad-P
CSAd-M TR(Mix)” combination, the vaccines were mixed before being injected into left and right legs. In the “Ad-M CSAd-M TR” combination vaccine,
the PbCSP vaccines were injected into the left leg, and the PbTRAP vaccines were injected into the right leg. (A) PbCSP-specific whole IgG serum Ab titers
measured 2 weeks after boost by endpoint ELISA. *,P 0.05 (as determined by unpaired t test). Means with the SEM are shown. Two weeks after boost mice were
challenged with 2,000 P. berghei. (B and C) Kaplan-Meier survival curves based on predicted time to 1% parasitemia.
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sis, receptor-mediated phagocytosis, and/or perhaps inhibition of
sporozoite binding to the liver (66). Touray et al. demonstrated an
almost complete lysis in vitro of P. gallinaceum sporozoites by
anti-sporozoite Abs and mammalian serum compared to only 11
to 15% lysis observed using nonimmune serum (67). The serum
samples from RTS,S-immunized volunteers contained opsoniz-
ing abs and these antibodies significantly enhanced in vitro endo-
cytic activity of the FcR() THP-1 human monocyte line in pro-
tected volunteers compared to those susceptible to sporozoite
infection (68). Complement fixation and endocytosis of op-
sonized sporozoites relies in part on the Fc region of the Ab. How-
ever, in the present study no such role for the Fc region was dis-
covered. In fact, the Fc-independent neutralization of P. berghei
sporozoites is in agreement with a previous observation where
comparable levels of neutralization were achieved upon opsoniza-
tion ofP. berghei sporozoites with either intact or Fab fragments of
3D11 (32). However, it remains unclear whether Fc-independent
phagocytosis was occurring and, if so, what was its contribution to
the protection induced by the Ad-M TR3D11 combination vac-
cine.
The decreased level of protection obtained after depletion of
NK cells is consistent with studies performed by Doolan and Hoff-
man (69), where protective immunity by irradiated P. yoelii
sporozoites or plasmid DNA-vaccinated mice was mediated by
effector CD8 T cells and NK cells and depended on interleu-
kin-12 (IL-12), IFN-, and nitric oxide (NO). Moreover, in a fol-
low-up study, the same authors established that perforin, gran-
zyme B, and Fas L (Fas ligand) were not required for the
protection induced by irradiated P. yoelii sporozoites (45). These
authors suggested that the protective response is initiated by an-
tigen-specific CD8 T cells that upon recognition of specific pep-
tide-MHC complexes secrete IFN-, which, in turn, induces IL-12
secretion from innate immune cells, such as macrophages, den-
dritic cells, or monocytes. The IL-12 subsequently stimulates the
NK cells, which then may directly kill infected hepatocytes or in-
duce antiparasitic activity through the secretion of IFN-. The fact
that the depletion of NK cells significantly abrogated protection in
this study provides some support for this model. This could also
explain the strong correlation between CD8 IFN- and NK
IFN- lymphocyte subsets that was observed and is consistent
with publications suggesting that NK-specific IFN- responses
may be tightly associated with the T-cell responses at the preeryth-
rocytic stage (70), as well as the blood stage (71), of infection. The
cytotoxic activity of CD8 T cells has also been demonstrated to
be one of the principal mediators of protection against sporozoite
challenge (45, 72).
Significantly higher numbers of CD8 T cells were measured
in the livers of mice that were immunized with ChAd63-PbTRAP
than in the livers of naive animals. Potent TRAP-specific cellular
immune responses were also measured 2 weeks after the ChAd63-
PbTRAP prime by ex vivo IFN- ELISPOT assay.
Previous studies have found a role for cytotoxic CD8 T cells
and IFN- in mediating protection, including with CSP (33, 49–
51). These could play a role in the protection mediated by the
vaccine regimens presented here: although depletion of CD4 and
CD8 T cells did not abrogate the protective effect of the Ad-M
CSP vaccine, this may be because anti-CSP antibodies played the
FIG 6 Immunological mechanisms of the 3D11 and Ad-M PbTRAP combination vaccine. C57BL/6 mice (n 
 6 per group) were vaccinated with a
heterologous prime-boost regimen using ChAd63 and MVA viral vectors expressing PbTRAP. A control group (n
 6) was vaccinated with empty vector
control viruses. (A) The role of the Fc region in protection was investigated using a sporozoite neutralization assay. A total of 50,000 P. berghei spz were
incubated with either intact or Fab fragments of 3D11 at a range of concentrations. A total of 5,000 sporozoites, each opsonized with either 3D11 or 3D11
Fab, were then i.v. injected into Ad-M PbTRAP-vaccinated animals. The percentages of animals experiencing sterile protection are shown. (B) Two weeks
after boost and on days3,2, and1 relative to challenge with 2,000 P. berghei spz, vaccinated animals were injected with 120 g of 3D11 MAb each day.
Control mIgG1 was administered in an identical manner. Additionally, either NK (NK) or Kupffer (Kf) cells in the vaccinated animals were depleted by
multiple i.v. injections of either anti-asialo GM1 or clodronate liposomes, respectively, prior to challenge. An NK depletion control was included. The levels of
sterile protection were used to quantify the effects of different treatments on vaccine-induced protection. *, P 0.05; ns, nonsignificant [as determined by Fisher
exact test comparing the indicated group to the (Ad-M PbTRAP)mIgG1 group]. (C) C57BL/6 mice were immunized with Ad-M PbTRAP or empty viral Ad-M
VC vaccines (n
 6 per group). Two weeks after boost animals were challenged with 200 P. berghei spz. Kaplan-Meier survival curves were determined based on
the predicted time to 1% parasitemia.
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principal role in protection, as evident from the strong correlation
with time to reach 1% parasitemia (Fig. 3Bi).
In summary, a highly protective vaccination regime was devel-
oped by combining two suboptimal subunit vaccines, CSP and
TRAP, in a P. berghei malaria mouse model. The successful vacci-
nation regime combined Ad-P CS and Ad-M TR. This elicited
strong Ab responses against CS and CD8T-cell responses against
TRAP, reducing the number of sporozoites reaching the liver and
FIG 7 ICS analysis of liver-resident lymphocytes. C57BL/6 mice (n
 5 per group) were immunized with a single ChAd63-PbTRAP vaccine (Ad) and 2 weeks
later challenged with 3,000 P. berghei spz. At 24 h after challenge, the livers from vaccinated challenged (Ad-Chal) and unchallenged (Ad-UnChal) animals were
extracted, and lymphocytes were purified and quantified. Livers from naive challenged (N-Chal) and unchallenged (N-UnChal) animals were also included. ICS
was performed, and samples were acquired using a BD LSRII flow cytometry instrument. The total number per mouse liver of CD8 T cells (A), iNKT cells (B),
and NK cells (C) was quantified (top panel), as well as the percentage (middle panel) and total number (bottom panel) of IFN- positive cells within each subset
for all treatment groups. (D) A strong correlation was obtained between the proportions of CD8 IFN- and NK IFN- cells for the Ad-UnChal group, but
not other groups. (E) The percentage (top panel) and total number (bottom panel) of NKCD69 cells per liver for each treatment group were determined. ****,
P 0.0001; **, P 0.01; *, P 0.05; ns, nonsignificant (as determined by two-way ANOVA). Means with the SEM are shown.
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causing the destruction of the lower number of infected hepato-
cytes.
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